Ratings Joinn Laboratories(China)Co.,Ltd. Hong Kong S.E.

Equities

6127

CNE100004BP3

Market Closed - Hong Kong S.E. Other stock markets 04:08:12 2024-06-17 am EDT			5-day change	1st Jan Change
8.18 ^HKD	+0.86%		+0.99%	-36.39%

Apr. 30	Nomura Adjusts Joinn Laboratories’ Prive Target to 17.37 Yuan From 21.01 Yuan, Keeps at Neutral	MT
Apr. 30	Nomura Adjusts Joinn Laboratories’ Price Target to HK$10.41 From HK$12.60, Keeps at Neutral	MT

Summary

From a short-term investment perspective, the company presents a deteriorated fundamental configuration.

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
The group's activity appears highly profitable thanks to its outperforming net margins.
Thanks to a sound financial situation, the firm has significant leeway for investment.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
Analyst opinion has improved significantly over the past four months.

Weaknesses

The company benefits from high valuations in earnings multiples.
With an enterprise value anticipated at 3.3 times the sales for the current fiscal year, the company turns out to be overvalued.
The company is highly valued given the cash flows generated by its activity.
The firm pays small or no dividend to shareholders. For that reason, it is not a yield company.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
The company's sales previsions for the coming years have been revised downwards, which foreshadows another slowdown in business.
For the past year, analysts have significantly revised downwards their profit estimates.
For the last twelve months, the analysts covering the company have given a bearish overview of EPS estimates, resulting in frequent downward revisions.
Over the past four months, analysts' average price target has been revised downwards significantly.
Sales estimates for the next fiscal years vary from one analyst to another. This clearly highlights a lack of visibility into the company's future activity.
The price targets of analysts who cover the stock differ significantly. This implies difficulties in evaluating the company and its business.

Ratings chart - Surperformance

Sector: Biotechnology & Medical Research

	1st Jan change	Capi.	ESG Refinitiv
JOINN LABORATORIES(CHINA)CO.,LTD.	-36.39%	1.41B	-
MODERNA, INC.	+40.80%	53.67B	B-
LONZA GROUP AG	+35.76%	38.86B	A
IQVIA HOLDINGS INC.	-8.05%	38.76B	B
CELLTRION, INC.	-8.98%	27.27B	C
ICON PUBLIC LIMITED COMPANY	+10.69%	25.91B	B-
ALNYLAM PHARMACEUTICALS, INC.	-16.21%	20.29B	B
UNITED THERAPEUTICS CORPORATION	+31.00%	12.78B	B+
MEDPACE HOLDINGS, INC.	+28.51%	12.18B	C+
BIO-TECHNE CORPORATION	-1.67%	11.96B	B+

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes